Many people have a dim view of the pharmaceutical industry, referred to by critics as the Big Pharma. This reputation is not helped by someone like Martin Shkreli, former CEO of Turing pharmaceuticals. Shkreli came under fire in 2015 when he raised the price of an anti-parasitic drug, Daraprim, from $13.50 to $750.
Daraprim can be a life-saving drug for patients with compromised immune systems like those with AIDS or cancer.
A Reuters report said Shkreli is facing trial this month but for reasons unrelated to the Daraprim price hike. Shkreli is facing fraud charges for what prosecutors say was a Ponzi-like scheme he undertook while he managed a hedge fund and a pharmaceutical company, Retrophin. He founded the drug company in 2011.
According to authorities, Shkreli lured investors into his hedge fund, which was already incurring massive losses. He allegedly lied about those losses and instead, stole millions of dollars from Retrophin to pay investors back.
On the heels of news on Shkreli, another pharmaceutical head, Barry Cadden, was sentenced to nine years in prison for conspiracy and fraud. According to CBS News, prosecutors accused Cadden of violating safety regulations at his facility, the New England Compounding Center. He supposedly did this to hasten production and increase profits.
Cadden was earlier charged with second-degree murder after contaminated medical steroids from his facility were injected into patients. Hundreds of people got sick and 76 died. Cadden was acquitted of the murder charge.
The tug-of-war between profit and public health is likely to continue as long as pharmaceutical firms are in business. One study posted in the National Center for Biotechnology Information website said the conflict of interest between the two is technically unsolvable. The study proposed an “extension of morality” in the existing system and public policy to help reconcile public good with private enterprise.
Global earnings for pharmaceutical companies are estimated at more than a trillion dollars per year. In the U.S. alone drug companies poured $790 billion into the economy. They also support 3.4 million jobs, directly and indirectly. With so much at stake, it’s unclear where this moral shift will come from.
International fintech companies Cred and Responsive enter Nexi Open
Cred is a financial technology company based in Tel Aviv and operating in the United States and Western Europe. The...
BHV Partners plans to triple its portfolio and create an investment fund in 2021
BHV Partners, a venture builder specialized in the health sector is looking to invest in up to 15 companies next...
The Colombian Senate approves the legalization of recreational cannabis
The Colombian Senate approved the first initiative to regulate the use of cannabis by adults and paves the way for...
Endesa and Parkia join forces to install electric recharging points
Endesa hopes to close the year with 8,000 recharge points installed in Spain, both public and private, and multiply them...
Caldas Gold, the company that exploits the legendary Marmato gold mine
The company Caldas Gold will take the name Aris Gold, as recently announced, after initiating financing with investors, which will...
Featured6 days ago
Naturgy and Eni to share Union Fenosa Gas and seek to solve the dispute with Egypt
Featured5 days ago
How are ESG company news deciphered with Artificial Intelligence
Business6 days ago
How to identify customer tastes? Wine innovation may hold the key.
Africa6 days ago
A budget of 123.5 billion francs for construction work on Bugesera Airport